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Abstract 
Ly6/uPAR/α-neurotoxin domain (LU-domain) is characterized by the presence of 4–5 disulfide 
bonds and three flexible loops that extend from a core stacked by several conversed disulfide bonds 
(thus also named three-fingered protein domain). This highly structurally stable protein domain is 
typically a protein-binder at extracellular space. Most LU proteins contain only single LU-domain as 
represented by Ly6 proteins in immunology and α-neurotoxins in snake venom. For Ly6 proteins, 
many are expressed in specific cell lineages and in differentiation stages, and are used as markers. In 
this study, we report the crystal structures of the two LU-domains of human C4.4A alone and its 
complex with a Fab fragment of a monoclonal anti-C4.4A antibody. Interestingly, both structures 
showed that C4.4A forms a very compact globule with two LU-domain packed face to face. This is 
in contrast to the flexible nature of most LU-domain-containing proteins in mammals. The Fab 
combining site of C4.4A involves both LU-domains, and appears to be the binding site for AGR2, a 
reported ligand of C4.4A. This work reports the first structure that contain two LU-domains and 
provides insights on how LU-domains fold into a compact protein and interacts with ligands. 
Key words: C4.4A, uPAR, three-fingered fold, LU-domain. 
Introduction 
Proteins with Ly6/uPAR/α-neurotoxin domain 
(LU-domain), also named three-fingered protein 
domain or TFPD, are widespread in the animal 
kingdom and mainly comprises either secreted or 
glycosyl-phosphatidylinositol (GPI) anchored single 
domain proteins with diverse biological functions [1]. 
The hallmark of a prototypical LU-domain is 8 
conserved cysteine residues engaged in a defined 
disulfide-bonding, which forms a compact 
cysteine-rich knot (palm) projecting three extended 
loops (fingers) stabilized by 5–6 β-strands [2-4]. This 
domain fold has been extensively utilized in the 
evolution of a variety of snake venom toxins targeting 
acetylcholine receptors (e.g., α-neurotoxins), 
acetylcholine esterases (e.g., fasiculin), L-type calcium 
channels (e.g., calciseptins) or targeting cell 
membranes (e.g., cardiotoxins) [4]. In a coral snake, up 
to 95% of its venom toxin are TFP toxins [5]. In 
mammals, secreted or GPI-anchored single 
LU-domain-containing proteins are also important 
mediators of diverse aspects of physiology including 
inhibiting autologous complement activation (CD59) 
[6], modulating neuronal acetylcholine receptors 
(Lynx1 and SLURP1) [4, 7], and securing efficient 
intravascular triglyceride hydrolysis by trafficking 
and stabilizing lipoprotein lipase (GPIHBP1) [8-10]. 
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Notwithstanding the prevalence of single 
LU-domain-containing proteins in the animal 
kingdom, there are only a few examples where two or 
more LU-domains forming the functional unit. In 
venomous snakes, certain neurotoxins evolved 
unique functions via homodimeric assembly using 
either non-covalent interactions (e.g., κ-bungarotoxin 
and haditoxin) [11, 12] or covalent disulfide linkage 
(e.g., iriditoxin and α-cobratoxin) [13, 14]. In 
mammals, CD59 forms dimer, and further to 
oligomers, in lipid rafts of cell surface and induce 
intracellular Ca2+ response [15]. Significantly, a small 
gene cluster located on chromosome 19q13 in humans 
encodes GPI-anchored proteins containing 2–4 
consecutive LU-domains (e.g., uPAR, C4.4A, Haldisin, 
TEX101, CD177, and PINLYP) [2, 16]. These multiple 
LU-domain-containing membrane proteins evolved 
diverse important roles. For instance, uPAR plays 
important roles in focalizing plasminogen activation 
on cell surfaces and regulating cell motility and 
immune response [16]. The elevated soluble uPAR 
level in plasma is associated with incident acute [17] 
or chronic kidney disease [18], cardiovascular disease 
[19], and human cancer [20]. The CD177 mediates 
neutrophil endothelial transmigration [21, 22], and its 
overexpression is associated with chronic 
myeloproliferative disorders [23]. TEX101 regulates 
fertility [24]. C4.4A and Haldisin define stages of 
squamous epithelial differentiation [25-27]. 
Despite the clear functional importance of these 
multiple LU-domains proteins, their 
three-dimensional structures remain largely 
unexplored with a single exception. The 
urokinase-type plasminogen activator receptor 
(uPAR) is a GPI-anchored membrane protein 
containing three LU-domains (DI, DII and DIII) and 
several crystal structures have been solved for this 
founder of the LU-domain protein family [28-32]. The 
intermolecular assembly of all three LU-domains in 
uPAR via β-sheet interactions creates a large central 
hydrophobic ligand-binding cavity that mediates the 
high-affinity binding of its primary ligand, the serine 
protease urokinase-type plasminogen activator.  
Biophysical studies have shown that this interdomain 
assembly in uPAR is highly flexible and that this has 
biological relevance [33, 34]. Restricting this internal 
flexibility by introducing an interdomain disulfide 
bond between the DI and DIII traps uPAR in a closed 
conformation, which increases its affinity for its 
second ligand, Vitronectin [33, 35]. From a 
translational perspective, this domain flexibility also 
proved essential for the development of a small 9-mer 
peptide targeting an intermediate conformation in 
uPAR [28, 36] and this assisted its further maturation 
into a PET-probe currently used for non-invasive 
imaging of uPAR expression in patients with 
malignant solid tumors [37-39]. Moreover, the dimer 
of uPAR isoform 2 was reported to induce kidney 
diseases in mice [40]. 
Prompted by the close relationship between 
LU-domain flexibility and function of uPAR, we 
decided to solve the crystal structure of another 
protein containing multiple LU-domains to gain 
further insight into the structural versatility of this 
fold. We chose to focus on C4.4A (encoded by 
LYPD3), which contains two LU-domains followed by 
a mucin-type region rich in serine, threonine and 
proline (STP-rich region) and a C-terminal 
GPI-anchor [41, 42]. No well-defined function has yet 
been assigned to C4.4A, but circumstantial evidence 
suggests that it could play a role in cell adhesion, 
migration and invasion through established 
interaction with laminins [43], integrins and MMP14 
[44, 45], and/or Anterior Gradient 2 (AGR2) [46]. 
Nonetheless, expression of C4.4A is strictly regulated 
under normal homeostatic conditions as it represents 
a robust biomarker for the presence of stratum 
spinosum in stratified squamous epithelia of the skin 
and for squamous differentiation of epithelia in other 
organs such as esophagus, vagina, oral cavity, and 
rectum [27, 42, 47]. Along the same lines, squamous 
metaplasia of bronchial epithelia (not yet a malignant 
lesion) is strictly correlated with the emergence of 
C4.4A expression [48]. Consequently, high expression 
levels of C4.4A predicts poor prognosis for patients 
with pulmonary adenocarcinoma but not for those 
with squamous cell carcinoma [20, 49, 50]. Similar 
findings have been reported in other solid cancers in 
e.g., breast [51], bladder [52, 53], colon [54, 55], and 
esophagus [56, 57]. Based on these findings, there is a 
strong interest in studying C4.4A in various 
pathological conditions and new experimental tools 
are being developed to accomplish this—such as 
C4.4A-deficient mouse models [53] and antibody 
drug conjugates targeting C4.4A [58]. With this study, 
we seek to gain structural insights into how the 
LU-domains in C4.4A are organized and how C4.4A 
recognizes ligand. 
Results 
Challenges in structural determination of 
C4.4A 
Recombinant human C4.4A was expressed in 
Drosophila S2 cells. This recombinant protein contains, 
at its C-termini, a purification tag (uPAR DIII) to 
facilitate the capture and purification of the protein 
[59]. The STP-rich region of C4.4A is heavily 
glycosylated containing 15 putative O-linked 
glycosylation sites [42], posing major difficulty for the 
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crystallization of intact C4.4A. We thus removed the 
STP-rich region and the purification tag by limited 
proteolysis with chymotrypsin to obtain the 
N-terminal region containing the two LU-domains 
(DI and DII) of C4.4A (residues 1–201), which was 
then purified to high homogeneity, and grown into 
well diffracting crystals of C4.4A (2.4 Å) at pH 3.6 [60]. 
Structural determination from these C4.4A crystals 
using molecular replacement (MR) proved difficult 
due to the low sequence conservation amongst 
published structures of single LU-domain (e.g., the 
two LU-domains in human C4.4A share only 30% and 
28% sequence identity with the DII of uPAR). 
Single-wavelength anomalous dispersion phasing 
using a biosynthetically selenomethionyl labeled 
C4.4A (yielding ~70% Se-incorporation in Met) was 
unsuccessful due to poorly diffracting SeMET crystals 
(>4 Å). Traditional multiple isomorphous 
replacements (MIR) or phasing with sodium bromide 
[61] were also tried, but in all cases, the crystals either 
lost their diffraction upon soaking or did not give 
clear solutions of heavy atom positions. 
 
Table 1. Data collection and structure refinement statistics. 
 C4.4A C4.4A:Fab 
Data Collection and scaling 
Resolution range 49.309 - 2.59 
(2.69 - 2.59) 
40.144 - 2.75 
(2.85 - 2.75) 
Space group C 2 2 21 P 1 21 1 
Cell dimensions   
a, b, c (Å) 57.1, 120.2, 169.4 51.9, 64.0, 107.7 
α, β, γ (º) 90, 90, 90 90, 96.1, 90 
Unique reflections 18403 (1763) 18267 (1809) 
Redundancy 7.7 (8.1) 3.7 (3.8) 
Completeness (%) 99.49 (97.18) 98.91 (99.07) 
I/σ(I) 37.58 (3.76) 8.90 (2.09) 
Wilson B-factor 55.43 54.15 
R-mergea 0.094 (0.690) 0.1134 (0.8406) 
Refinement 
R-work 0.2063 (0.3126) 0.1963 (0.3068) 
R-free 0.2503 (0.3349) 0.2555 (0.3484) 
Average B-factor (Å2) 70.46 77.20 
  Macromolecules 69.53 77.04 
  ligands 96.99 90.27 
Validation 
RMSD from ideal   
Bond lengths (Å) 0.011 0.013 
Bond angles (°) 1.63 1.88 
Ramachandran plot   
favoured (%) 92.80 95.30 
outliers (%) 0.00 0.50 
PDB code 6IOM 6ION 
Statistics for the highest-resolution shell are shown in parentheses. 
aRmerge=Σ|Ii-<I>|/ΣIi, where Ii is the intensity of the ith observation and <I> is the 
mean intensity of the reflections. 
 
 
The complex between C4.4A and the Fab 
fragment of 11H10 was purified by size exclusion 
chromatography and yielded well-diffracting crystals 
of C4.4A:Fab (11H10). The Fab fragment was 
positioned into the crystal by MR, and the Fo-Fc map 
now revealed electron density for C4.4A. Extensive 
manual building, together with iterative refinement, 
finally yielded crystal structures of both the 
C4.4A:Fab complex and C4.4A with good statistics. 
The structure of C4.4A was refined to 2.59 Å with 
R-factor and R-free of 0.2063 and 0.2503, respectively; 
92.8% residues in favored Ramachandran region 
(Table 1). Most residues of the C4.4A structure are 
well supported by electron density maps, except for 
residues 95–99 and residues 92–101—a glycosylated 
linker region between the DI and DII—which were 
consequently not modelled in the structure. The 
structure of C4.4A:Fab complex was refined to 2.75 Å 
with R-factor and R-free of 0.1963 and 0.2555, 
respectively; 95.3% residues in favored 
Ramachandran region (Table 1). Residues 89–103 of 
C4.4A molecule between DI and DII are also not 
modelled. 
Crystal structure shows that the two 
LU-domains in C4.4A forms a compact and 
globular unit 
The current crystal structure (Fig. 1) shows that 
each LU-domain (DI, residues 1–91, DII, residues 102–
201) in C4.4A contains six β-strands (DI: βIA, regions 
2–9; βIB, 20–23; βIC, 31–40; βID, 43–52; βIE, 58–66; 
βF6, 69–78; DII: βIIA, 109–111; βIIB, 128–130; βIIC, 
141–151; βIID, 154–164; βIIE, 172–176; βIIF, 179–187) 
providing a scaffold for the assembly of three 
protruding loops (also named fingers: F1, βA to βB; 
F2, βC to βD; F3, βE to βF)—one of the topological 
hallmarks defining the archetypical three-fingered 
fold [4, 28]. At the disulfide-rich base (“palm region”), 
three linker regions (Lk1, Lk2 and Lk3) join the 
individual loops (i.e., F1 to F2 by connecting βB–βC, 
F2 to F3 by connecting βD–βE, and F3 to the 
C-terminal region via βF). Notably, the DII-Lk1 
connecting βIIB and βIIC of C4.4A is quite long (9 
amino acids vs only 6 in the DI-Lk1). The six β-strands 
in the DI form a large continuous β-sheet (61% β-sheet 
content), whereas the DII has a small β-sheet (49% 
β-sheet content) (Fig. 1D).  
A long inter-domain linker exists between the 
two LU-domains in C4.4A. However, the two 
LU-domains assemble via a large hydrophobic 
interface to form a compact protein structure with the 
dimensions 60 x 42 x 34 Å (Fig. 1A, B and C). This 
unique assembly of the LU-domains in C4.4A 
resembles two right hands tightly facing each other on 
finger area. 
There are two C4.4A molecules in the 
asymmetric unit of the crystal. Superposition of the 
two molecules shows that their structures are highly 
similar with each other with RMSD of 0.72 Å for all 
Cα, further supporting the low flexibility of the 
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structure under these conditions. Another notable key 
difference between the two LU-domains in C4.4A is 
the arrangement and the number of disulfide bonds. 
The DI has four disulfide bonds (Db1, Cys3–Cys31; 
Db1a, Cys6–Cys14; Db2, Cys24–Cys52; Db4, Cys78–
Cys83), while the DII has five (Db1, Cys110–Cys142; 
Db1a, Cys113–Cys121; Db2, Cys131–Cys163; Db3, 
Cys169–Cys185; Db4, Cys186–Cys191) (Fig. 1D). This 
divergent arrangement of the disulfide bonding is 
nonetheless not unique to C4.4A, but is found in all 
proteins with multiple LU-domains. In these proteins, 
the N-terminal LU-domains invariably lack one of the 
otherwise consensus disulfide bonds (Db3) [2]. 
Paradoxically, missense mutations affecting one of the 
four consensus disulfides in the single LU-domain- 
containing proteins (e.g., GPIHBP1, CD59, κ- 
bungarotoxin) cause protein misfolding and 
loss-of-function [6, 12, 62, 63]. One possible structural 
advantage of the absence of Db3 in the DI is that the 
affected βID becomes much less twisted compared to 
the corresponding βIID in the DII (where Db3 remains 
intact). A comparison to all structures solved for 
uPAR reveals similar lower twisting of βID compared 
to βIID [28-32].  
The crystal structure revealed clearly four 
N-linked glycans (Fig. 1A, D), including one located at 
the linker regions between the LU-domains of C4.4A 
(Asn88) and three glycans in the DII of C4.4A 
(Asn133, Asn146 and Asn153).  
 
 
Figure 1. The crystal structure of C4.4A and sequence alignment of different C4.4A. (A, B and C) Three perspective of the structure of C4.4A. The schematic 
drawings using two hands to show the relative orientation of the two domains. Both DI (cyan, residues 1–91) (B) and DII (green, residues 102–201) (C) contain 
similar six β-strands (βA to βF) and three linkers (Lk1 in color salmon, Lk2 in blue and Lk3 in purple). These β-strands constitute three fingers. The N-linked 
glycosylation are highlighted as grey sticks. The disulfide bonds are shown as yellow sticks. All structural figures here and below are prepared by PyMol [64]. (D) 
Sequence alignments of the C4.4A from different species. Strictly conserved amino acids are show in red background while strictly conserved disulfide bonds (Db1, 
Db2 and Db4) in solid line and highly conserved disulfide bonds (Db1a and Db3) in dash lines. The α-helix and β-strand of secondary structure are shown above the 
sequence as spiral curve and arrow, respectively. Diamonds denote potential N-linked glycosylation sites. The sequence alignment was made by ESPript 3.0 [65]. 
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Structural basis for a compact conformation of 
C4.4A 
The two LU-domains of C4.4A associate tightly 
in the crystal structure forming a globular protein. 
This domain organization is predominantly stabilized 
via interdomain hydrophobic interactions involving 
relatively large surfaces of the central β-sheet in each 
LU-domain (Fig. 2A, B). Of note, the central β-sheets 
of the two LU-domains in C4.4A are both asymmetric 
in the sense that they have one face which is 
particularly hydrophobic (hydrophobic contact area 
of 562 Å2 for DI and 638.6 Å2 for DII) (Table S1). These 
hydrophobic faces of the β-sheets assemble to form 
the interdomain binding interface and they share a 
high degree of shape complementarity. A number of 
polar interactions are also found at the rim of the 
interdomain interface: Ile41–Tyr132, Arg62–Thr175, 
His67–Gln165, His67–Asp172, Gly68–Tyr139 (Table 
S2, Fig. 2C). These hydrogen bonds and ionic 
interactions likely provide a directional force to 
stabilize the relative orientation between two 
LU-domains. Interestingly, these polar interactions 
are predominantly located at the interface created by 
the shape complementarity between the finger tips in 
the DI (finger tips of F2 and F3) and the disulfide rich 
core of the DII (including Lk1 and Lk2). In this region, 
the DII forms a highly negatively charged pocket 
(Asp166 and Asp172) that accommodates His67 from 
the DI by electrostatic interaction (Fig. 2D). This 
pocket is stabilized by Db3. 
Antibody 11H10 recognized both LU-domains 
in C4.4A 
The structure of C4.4A in the complex with the 
Fab fragment of mAb 11H10 is highly similar to the 
C4.4A alone (Fig. 3A), with an RMSD of 0.55 Å for all 
atoms. This high similarity demonstrates the 
compactness and rigidity of the globular assembly of 
the two LU-domains in C4.4A is not affected by the 
crystal lattice formation and the presence of the 
antibody. Note that the complex was crystallized 
under neutral pH (7.0), compared to the low pH (3.6) 
crystallization of C4.4A, which further underlines the 
stability of the compact structure of C4.4A.  
As shown by the C4.4A:Fab complex structures, 
the structural epitope on C4.4A recognized by the Fab 
fragment is mainly located in three β-strands (βC, βE 
and βF) in DI and the linkers between β-strands in DII 
(Lk1 and Lk2) (Fig. 3C, Table S3). The Fab Arg103 of 
heavy chain (labeled as H/Arg103 in Fig. 3C) inserts into 
the groove of C4.4A-DI and C4.4A-DII and forms 
hydrogen bonds with Asp65 and Gln165 of C4.4A 
(Table S2). On the other hand, C4.4A-DI residues 
Leu70 and Phe72 embed into the hydrophobic area 
surrounded by Fab heavy chain (Phe32, Trp54, Trp55, 
Tyr58, Tyr60 and Leu102) and light chain (Trp94 and 
Pro95).  
 
 
Figure 2. The crystal structure of C4.4A. Open-book illustration of the two 
C4.4A domains shown in electrostatic surface (A) and cartoon (B) 
representations. The interaction between the two LU-domains is mediated 
mainly by hydrophobic force (orange circle) together by some polar interaction 
(black circle). Two LU-domains have high complementarity in shape. Blue 
indicates positive potential and red indicates negative potential. The polar 
interaction between two domains of C4.4A is mainly located in the palm of DII 
and the tip of fingers (F2 and F3) of DI. The connecting peptide between βIID 
and βIIE in DII (Lk2, blue arrow) is twisted toward its central 3-stranded 
β-sheet. The Lk1 (orange arrow) connecting βIIB and βIIC adopts a similar 
orientation. (C) Polar interaction (yellow dashed lines: Ile41 to Tyr132; His67 
to Gln165; His67 to Asp172; Gly68 to Tyr132; Arg62 to Thr175) contribute to 
the formation of interaction between the two LU-domains. (D) A negatively 
charged pocket in DII (harboring Asp166 and Asp172 and stabilized by Db3) is 
occupied by His67 in the tip of DI-F2. 
 
Usually, the conformation of loop is susceptible 
to ligand binding and/or environment due to its 
flexibility. However, despite containing a long loop in 
DII-Lk1, the binding of Fab doesn’t induce the 
conformational change of this loop. Further structural 
analysis shows Tyr132 and Tyr139 located in DII-Lk1 
form hydrogen bonds with DI to stable the 
conformation of DII-Lk1 (Fig. 3B). Moreover, the 
DII-Lk1 appears to have constrained conformation 
due to the presence of four internal hydrogen bonds 
(Tyr132–Ala134, Asn133–Asp136, Ala134–His137, 
His137–Tyr139). All hydrogen bonds are mediated by 
the main chain atoms and thus are conserved in 
different species. 
The structure of the complex demonstrates that 
the mAb 11H10 recognizes a conformational epitope 
on intact C4.4A-DIDII containing both LU-domains. 
This observation is excellently aligned with 
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biochemical results showing by Western Blot (Fig. 3D, 
E) that the binding of mAb 11H10 to C4.4A requires 
that both domains are present and that it is folded 
correctly (line 4 and 6). 
Discussion 
The functional site of C4.4A for ligand binding 
C4.4A was reported to interact with both α6β4 
integrin and MMP14, promoting wound healing and 
metastasis [45]. In addition, the interaction between 
C4.4A with Anterior Gradient 2 (AGR2) stimulates 
pancreatic ductal adenocarcinoma cell aggressiveness 
and reduces sensitivity to chemotherapy drug 
gemcitabine. C4.4A also binds to integrin β1 and 
laminins 1 and 5 [46]. However, the structural details 
of how C4.4A interacts with its ligands is unknown.  
Based on our crystal structure of C4.4A:Fab 
complex, we studied its molecular interaction of 
C4.4A with AGR2 by carrying out the protein-protein 
docking between C4.4A and AGR2 (PDB ID: 2lnt) [66] 
using ZDOCK (Version 3.0.2) [67]. The top docking 
solution clearly stands out from all the rest of the 
solutions, demonstrating the top solution is highly 
reliable. Interestingly, the AGR2 contacts to C4.4A at 
the site (Fig. 4A) quite close to the Fab fragment 
binding site (Fig. 3A). Again, the C4.4A DII-Lk1 
moiety plays an important role mediating the 
interaction by docking into a pocket of AGR2 (Fig. 
4B). These consistent results demonstrate that this 
area of C4.4A is important for ligand binding. 
 
 
 
Figure 3. The crystal structure of C4.4A:Fab complex. (A) The mouse monoclonal anti-human C4.4A antibody (11H10) recognizes a composite epitope on human 
C4.4A that is assembled by the strands of DI (cyan) with the linker between strands of DII (green). The light chain and heavy chain of antibody are colored gray and 
violet, respectively. (B) The internal hydrogen bond network in both DII-Lk1 of C4.4A and C4.4A:Fab complex. All residues, except Tyr132 and Tyr139, are shown 
in sticks only main chain atoms. The DI residues are colored in cyan. (C) The details of interaction between C4.4A and Fab shows that Fab fragment (shown in surface 
with a 60% transparency) is get caught by C4.4A (shown in ribbon) thought three β-strands (βIC, βIE and βIF) of DI and the linkers between β-strands of DII (Lk1 and 
Lk2). The key residues of C4.4A are shown in sticks and labeled. (D and E) Mapping domain reactivity of mAb 11H10 with various C4.4A fragments constructs. (D) 
Silver stained SDS-PAGE gel of purified C4.4A domain constructs fused to a C-terminal uPAR DIII purification tag: C4.4A-DI1–107 (lanes 1 and 7), C4.4A-DII108–199 
(lanes 2 and 8), C4.4A-STP200–278 (lanes 3 and 9), C4.4A-DIDII1–199 (lanes 4 and 10), C4.4A-DIISTP108–278 (lanes 5 and 11), and C4.4A1–278 (lanes 6 and 12). Samples in 
lane 1–6 were unreduced, while samples in lane 7–12 were reduced and alkylated prior to SDS-PAGE. (E) An identical set of samples were immobilized on a 
PVDF-membrane. After blocking excess of binding sites, the PVDF membrane was incubated with 1 µg/mL of mAb 11H10 as primary antibody and was visualized by 
enhanced chemiluminescence. The results show mAb 11H10 only reacts with constructs containing both LU-domains in C4.4A and only if the disulfide bonds 
remained intact (lanes 4 and 6). 
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Figure 4. The molecular model of C4.4A (cyan & green) complex with AGR2 (violet). (A) Overall structure of C4.4A:AGR2 is quite similar to C4.4A:Fab (Fig. 3A). 
(B) The details of interaction between C4.4A and AGR2. The DII-Lk1 of C4.4A inserts into the hydrophilic pocket of AGR2 (violet surface and sticks). The βIC, βIF, 
and βIE strands of DI also interact with AGR2. 
 
A novel assembly mode of LU-domains in 
C4.4A 
LU-domains contain three to six highly 
conserved disulfide bonds with a unique signature 
motif: CCxxxxCN (x is arbitrary amino acid), which 
is tightly packed at the palm region [68]. 
In many cases, the palm surface of LU-domain 
is important in interacting with the ligand, as 
shown by the structure of the multiple-LU-domains 
protein (uPAR) and single LU-domain protein 
(CD59 and some three-fingered snake venom 
toxins) [29, 69-71]. The uPAR contains three 
LU-domains, which assemble in a circular manner 
by interdigitating with each other to generate a 
central cavity (Fig. 5B) which accommodate its 
ligand. However, in our C4.4A structures, the palm 
surfaces of two domains are composed wholly of 
hydrophobic residues and buried inside the protein 
by the unique face-to-face assembly mode of two 
LU-domains.  
A novel mode of homodimerization of 
LU-domains was revealed in our C4.4A structure. 
All of known three-fingered snake venom toxins 
contains only one LU-domain. A few toxins exist 
nevertheless as non-covalent homodimers in 
solution e.g. κ-bungarotoxin and haditoxin [11, 72]. 
In these dimers, two independent protein molecules 
are arranged in an antiparallel manner (Fig. 5C). 
The interaction between the protomers consist of 
the pairing of β-strands and van der Waals 
interactions provided by some hydrophobic 
residues in the F3. The key residue Phe49, which is 
found in all four κ-bungarotoxins to provide the 
hydrophobic core, interact with Ile20, Thr60 and the 
disulfide bond Cys46–Cys58 from another subunit 
[12, 73]. Three-fingered snake venom toxins also 
form homodimers or heterodimers via 
intermolecular disulfide bonds [74]. In the 
α-cobratoxin homodimer, the first N-terminal 
β-strand of two protomers were swapped, and two 
intermolecular disulfide bonds were formed 
between Cys3 in one protomer and Cys20 in 
another (Fig. 5D) [13].  
Prediction of structure of Haldisin, a C4.4A 
analogue, based on C4.4A structure 
Haldisin (encoded by LYPD5) is extracellular 
protein predominantly expressed in stratum 
granulosum of human skin under homeostatic 
condition, and was predicted to contain two LU- 
domains with disulfide bonding pattern similar to 
C4.4A [25]. However, the sequence identity 
between Haldisin and C4.4A is low, particularly for 
the DI (Fig. S1). Despite this low sequence 
conservation, we were able to generate a homology 
model of Haldisin based on our structure of C4.4A. 
The model was subjected to thorough molecular 
dynamics (MD) simulation. The stability, sampling 
and convergence of the MD simulation were 
established by calculation of the backbone RMSD 
(Fig. S2). Hess analysis and RMSD both confirmed 
the adequate sampling of Haldisin conformation 
around the equilibrium position in the last 500 ns of 
the MD simulation (Table S5). The most 
representative model of Haldisin, covering 92% of 
the sampled conformations was identified by 
clustering analysis on the last 500 ns MD trajectory. 
The resultant Haldisin model showed high 
structural similarity to our crystal structure of 
C4.4A with the RMSD of 1.58 Å (DI) and 2.16 Å 
(DII) for all Cα atoms (Fig. 6A). Importantly, the 
inter-domain interface of Haldisin is highly 
complementary to each other in term of charges 
(Fig. 6B blank circles) and polarity (Fig. 6B orange 
circles). Such high degree of structural similarity of 
Haldisin to C4.4A suggests parallel functions, 
which remains to be confirmed experimentally. 
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Figure 5. Different ways of LU-domain association. The assemble mode in crystal structures of (A) C4.4A (PDB ID: 6IOM), (B) uPAR (PDB ID: 2FD6), (C) 
β-Bungarotoxin homodimer (PDB ID: 1KBA) and (D) α-cobratoxin homodimer (PDB ID: 4AEA). Selected involved in interaction side chains were shown in sticks. 
Disulfide bonds were shown in yellow sticks. 
 
Figure 6. The structural model of Haldisin and C4.4A. (A) The superposition of Haldisin (DI colored in cyan, DII colored in green) and C4.4A (grey) shows that two 
structures fit well except some deviation of βIIE of DII. The inter-domain assembly of Haldisin is similar to C4.4A. (B) shows the surface electrostatic potential of the 
LU-domains the same orientation as in (A). 
 
Experimental procedures 
Generation of a monoclonal anti-C4.4A 
antibody and its Fab fragment 
A mouse monoclonal anti-C4.4A antibody 
(11H10) was generated by conventional mouse 
hybridoma technology after immunizing FVB mice 
with purified recombinant human C4.4A produced in 
Drosophila S2-cells with a C-terminal uPAR DIII fusion 
tag that was removed by enterokinase treatment [56, 
75]. Purified 11H10 was treated with immobilized 
Ficin (Thermo Scientific, Rockford, Il, US) in the 
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presence of 25 mM L-cysteine and 1 mM EDTA at 
37°C for 1 h to produce Fab and Fc fragments. The 
reaction mixture was passed through a Protein A 
column to remove the undigested 11H10 and its Fc 
fragments. The Fab-containing flow-through fraction 
was further purified size exclusion chromatography 
using a Superdex 200. 
Sequencing the CDRs of mouse monoclonal 
anti-C4.4A antibody 11H10 
Hybridomas producing 11H10 mAb (IgG1κ) 
were cultured and used to generate cDNA for the 
corresponding light and heavy chains using the 
Cells-to-cDNATM II kit (Life Technologies) and the 
following primers: 
Vκ light-chain 5`-primer:  
TATGAATTCGACATTCTGATGACCCAGTCT;  
Cκ light-chain 3`-primer: 
AGCGGCCGCACACTCATTCCTGTTGAAGCT
CTTGAC; 
VH heavy-chain 5`-primer: 
TATGAATTCCAGGTTACTCTGAAAGAGTCT
GG; 
CH heavy-chain 3`-primer:  
AGCGGCCGCACAATCCCTGGGCACAATTTT
CTTGTC. 
The cDNAs were amplified with conventional 
PCR using the Platinum Pfx DNA Polymerase 
(Invitrogen) and products with the proper size (app. 
700 bp) were purified from a 1% agarose gel with the 
QiaQuick Gel Extraction Kit (Qiagen). The cDNAs 
were cloned into pBlueScript KS+ using the 
introduced EcoRI and NotI restriction enzyme sites 
(underlined in the primer sequences) and the Rapid 
DNA ligation kit (Roche). Subsequently, DH5α 
Competent cells were transformed and DNA was 
isolated from individual clones and analyzed by 
restriction enzyme digestion before sequencing. 
Five-six clones for each chain were sequenced and 
revealed 100% identical sequences. The amino acid 
sequences are shown below: 
11H10 Fab light chain:  
DILMTQSPAILSVSPGEGVSFSCWANQNIGTSI
HWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTD
FTLSINSVESEDIADYYCQQSNSWPIFTFGSGTKLEI
KRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPK
DINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMS
STLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRN
EC. 
11H10 Fab heavy chain: 
QVTLKESGPGILQPSQTLSLTCSFSGFSLNSFGT
GVGWIRQPSGKGLEWLAHIWWNDYKYYNAALES
RLTISKDTSNNQVFLKIASVDTADTATYYCARLRLR
YFDYWGQGTTLTVSSAKTTPPSVYPLAPGSAAQTN
SMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPA
VLQSDLYTLSSSVTVPSSTWPSETVTCNVAHPASST
KVDKKIVPRDC. 
Expression and purification of soluble human 
C4.4A 
Recombinant C4.4A-ent-uPAR-DIII fusion 
protein was produced in Drosophila S2 cells and 
purified by immunoaffinity chromatography as 
described [59, 75]. The C4.4A protein containing the 
two LU-domains was subjected to limited proteolysis 
with chymotrypsin preferential hydrolyzing the 
peptide bonds after Tyr200 or Phe201 in the linker 
region between the DII and the mucin-type 
C-terminal domain [42] and further purified by size 
exclusion chromatography using a Superdex75 
column [60].  
Immunoblotting Analysis 
The generation of various C4.4A domain 
constructs was produced in Drosophila S2 cells and 
purified by immunoaffinity chromatography as 
described [59]. After separation by SDS/PAGE an 
identical set of samples were immobilized on a 
PVDF-membrane (Millipore, Bedford, MA, U.S.A.). 
After blocking excess of binding sites, the PVDF 
membrane was incubated with 1 µg/ml of mAb 
11H10 as primary antibody and peroxidase 
conjugated swine anti-mouse immunoglobulins 
(Dako, Glostrup, Denmark) diluted 1:5000 as 
secondary antibody. Positive reactivity was visualized 
by enhanced chemiluminescence (ECL plus; 
Amersham). 
Formation of complex between C4.4A and 
11H10 Fab 
The Fab peak was pooled and mixed with 
C4.4A-DIDII and the resultant complexes purified by 
gel filtration on a Superdex 200 column (GE Life 
Sciences) with 20 mM Tris, 150 mM NaCl and pH 7.4 
as the running buffer. The eluted fragments contained 
the target complex were mixed and concentrated to 10 
mg/mL using an Amicon Ultra Centrifugal Filter 
Device (Millipore, USA) with a molecular mass cutoff 
of 10,000 Da, the aliquots were stored frozen at -80°C. 
Crystallization 
The C4.4A crystals were obtained at 293K by the 
sitting-drop vapor-diffusion method in a 
concentration of 10 mg/mL. The precipitant condition 
is 22.5% (w/v) polyethylene glycol 4000, 0.1 M citric 
acid in pH 3.6, as described previously [60]. For 
C4.4A:Fab complex, all crystallization trials were 
done at 295K using commercial screening kits (from 
Qiagen, XtalQuest and Hampton Research) with the 
Phoenix robot (Art Robbins Instruments). Optimized 
crystals grew in 20% PEG3350, 0.2M Potassium 
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sodium tartrate tetrahydrate, 0.1M Tris-HCl pH 7. 
Crystals appeared within the third day and grew 
larger over the course of 2 weeks. Slender rod-shaped 
crystals were carefully looped and frozen in ice-free 
liquid nitrogen after a quick soak in original mother 
liquor with 25% (v/v) glycol. 
Data collection and processing 
Prior to X-ray data collection, the crystals were 
transferred to the precipitant solution containing 25% 
(v/v) glycerol and flash-frozen in liquid nitrogen. 
Diffraction data for both C4.4A and C4.4A:Fab 
complex were collected on beamline X29 at 
Brookhaven National Synchrotron Light Source 
(NSLS) and were processed using the automated 
data-processing pipeline xia2 [76] with options that 
run XDS [77].  
Structural determination of C4.4A-Fab 
complex and C4.4A 
MR method was used to solve C4.4A:Fab 
structure. The Fab fragment was positioned into the 
crystal lattice using BALBES automated 
structure-solution pipeline. Model refinement and 
building were carried out in PHENIX and COOT 
reiterally until converged. Next, search models of 
C4.4-DIDII were prepared by Sculptor utility of the 
PHENIX suite to match the target sequence based on 
the published human suPAR structure (PDB 3BT2, 
chain U, the DI and DII of C4.4A share 30% and 28% 
sequence identity with suPAR DII respectively). No 
MR solution can be found with all these models 
alone. Importantly, with the Fab positioned, we 
obtained the MR solution of the model of DI, giving 
a z-score of translational function higher than 12.0. 
The log-likelihood gain (LLG) from Phaser was also 
positive, indicative of a successful MR solution. The 
model was adjusted according to electron density 
map in Coot.  
After several rounds of refinement of the DI in 
C4.4A:Fab crystal, the well-fit model of DI was used 
as the search model for C4.4A crystal dataset, which 
had higher resolution (2.6 Å) than C4.4A:Fab complex 
(2.8 Å). The MR using Phaser produced the 
successful solution, and identified both molecules in 
the asymmetric unit. Phenix Autobuild module was 
used to perform iterative model building, refinement 
and density modification, leading to an improved 
electron density map. Iterative cycles of model 
building and refinement were performed until the 
model cannot be improved.  
The model from the C4.4A crystal was then used 
as the searching model to successfully place into the 
C4.4A:Fab crystal by MR method with the positioned 
Fab as fixed model. The completed model of the 
complex was further improved by several cycles of 
refinement and manual adjustment until converged. 
All relevant data collection and refinement statistics 
were summarized in Table 1. 
Molecular dynamics simulation of Haldisin 
The homology model of Haldisin was built 
automatically by the SWISSmodel web server based 
on the crystal structure of C4.4A [78]. The model of 
Haldisin was inserted into a truncated octahedron 
water box with edge lengths of 71 Å, 71 Å, and 71 Å. 
The protonation states of residues were assigned 
according to the corresponding pKa values calculated 
by using the H++ webserver [79]. Two Na+ ions were 
added to counterbalance the charge of the protein. 
The system contained 8,630 water molecules and 
28,786 atoms in total. It was underwent MD 
simulations with AMBER ff99SB-ILDN force field 
[80-82] using the GROMACS 4.6.5 code [83]. The 
Åqvist potential [84] and TIP3P model [85] were used 
for the ions and for the water molecules, respectively. 
All bond lengths were constrained by LINCS 
algorithm [86]. Periodic boundary conditions were 
applied. Electrostatic interactions were calculated 
using the Particle Mesh-Ewald (PME) method [87], 
and van der Waals and Coulomb interactions were 
truncated at 10 Å. The system underwent 1,000 steps 
of steepest-descent energy minimization with 1,000 
kJ·mol−1·Å−2 harmonic position restraints on the 
protein, followed by 2,500 steps of steepest-descent 
and 2,500 steps of conjugate-gradient minimization 
without restraints. The system was then gradually 
heated from 0 K up to 298 K in 20 steps of 2 ns. After 
that, 2000 ns-long productive MD simulations were 
carried out in the NPT ensemble. The most 
representative structure was identified by the cluster 
analysis [83] with a cut-off of 1.5 Å over the 
equilibrated trajectories, ranging from 1500 ns to 2000 
ns. To assess the convergence of the simulated 
trajectory in the last 500 ns, we considered the 
projection of each snapshot on the top essential 
dynamical spaces obtained from a standard 
covariance analysis. Following Hess’s criterion [88], 
these projections were next compared with those 
expected for a random reference. The observed 
negligible overlap (i.e. cosine content close to 0, see 
Table S5) confirmed a posterior adequate sampling of 
Haldisin conformation around the equilibrium 
position in the last 500 ns. 
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